XML 29 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Corrections to Previously Issued Consolidated Financial Statements (Tables)
9 Months Ended
Jun. 30, 2017
Corrections to Previously Issued Consolidated Financial Statements [Abstract]  
Schedule of corrections and consolidated financial statements
  As of and for the Period Ended 
June 30, 2016
 
ITEMS Previously 
Reported
  Adjustments  Restated 
          
Consolidated Statements of Balance Sheets         
Prepayment  3,500,000   (3,500,000)  - 
Due to related party  -   6,500,000   6,500,000 
Accumulated deficit  (669,207)  (10,000,000)  (10,669,207)
             
Consolidated Statements of Operations and Comprehensive Loss            
For the nine months ended June 30, 2016            
Research and development expenses  -   10,000,000   10,000,000 
Net Loss  (352,796)  (10,000,000)  (10,352,796)
Basic and diluted loss per share  (0.00)  (0.05)  (0.05)
             
Consolidated Statements of Cash Flow            
Net loss from operating activities  (353,605)  (10,000,000)  (10,353,605)
Issuance of common stock for compensation  -   897,521   897,521 
(Increase) decreases in prepayment  (3,496,185)  3,500,000   3,815 
(Increase) decrease in due from related party  350,000   (350,000)  - 
Increase (decrease) in due to related party  (22,517)  6,500,000   6,477,483 
Increase (decrease) in due to shareholder  (46,586)  46,586   - 
Net cash used in operating activities  (3,857,447)  594,107   (3,263,340)
             
(Increase) decrease in due to shareholder  -   (46,586)  (46,586)
Proceeds from subscription receivable  -   350,000   350,000 
Proceeds from issuance of common stock  897,521   (897,521)  - 
Net cash used in financing activities  2,947,521   (594,107)  (2,353,414)
Schedule of adjustments on previously reported consolidated financial statements
  Previously 
Reported on Form 10K
  Adjustments No.1  Adjustments No.2  Restated 
             
Consolidated Balance Sheet            
As of September 30, 2016                
Due to related party  -   6,500,000   -   6,500,000 
Total Liabilities  56,470   6,500,000   -   6,556,470 
Additional paid-in capital  4,733,401   -   60   4,733,461 
Accumulated deficit  (4,823,401)  (6,500,000)  -   (11,323,401)
Total equity (deficit)  120,882   (6,500,000)  -   (6,379,118)
                 
Consolidated Statements of Operations and Comprehensive Loss                
For the year ended September 30, 2016                
Selling, general and administrative expenses  4,497,263   (3,500,060)  60   997,263 
Research and development expenses  -   10,000,000   -   10,000,000 
Net loss from operations  (4,497,295)  (6,499,940)  (60)  (10,997,295)
Loss from continuing operations before income taxes  (4,506,963)  (6,499,940)  (60)  (11,006,963)
Net Loss  (4,507,799)  (6,499,940)  (60)  (11,007,799)
Basic and diluted loss per share  (0.00)  (0.06)  (0.00)  (0.06)
Consolidated Statements of Cash Flow                

For the year ended September 30, 2016

                
Net loss from continuing operations  (4,507,799)  (6,499,940)  (60)  (11,007,799)
Issuance of common stock for compensation  1,295,324   (60)  60   1,295,324 
(Decrease) increase in due to related party  (22,517)  6,500,000       6,477,483 
                 

Consolidated Statements of Cash Flow

                
For the year ended September 30, 2015                
Net cash used in operating activities  (517)    -   (198)  (715)